Skip to content

Trial Summary

Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcom

Acronym:

NCT05218499

ACTRN/NCT /ethics:

NCT04047862

Scientific title:

Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma

Sponsor / Cooperative group:

Boehringer Ingelheim

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeTreatment
PhasePhase II; Phase III
Age Range18 years and older
SexAll
Tumour Stream Liposarcoma
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2022-03-25
Anticipated End Date2026-05-27

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Emailsue.yeend@icon.team
Phone08 8292 2204
Principal InvestigatorDr Nimit Singhal
Recruitment StatusNot Yet Recruiting